ARTICLE | Company News
Halozyme grants argenx access to Enhanze subcutaneous delivery tech
February 8, 2019 1:47 AM UTC
Halozyme Therapeutics Inc. (NASDAQ:HALO) granted argenx S.E. (NASDAQ:ARGX) exclusive rights to use Halozyme's Enhanze subcutaneous drug delivery technology in combination with any product targeting the human neonatal Fc receptor FcRn, including argenx lead compound efgartigimod (ARGX-113) and up to two additional targets...